NR3C2 and heart failure: The control group was treated with diuretics, antiplatelet aggregation, lipid-lowering and plaque-stabilizing agents, aldosterone receptor antagonists, ARNI, β-receptor blockers and other conventional biomedicine medicines for heart failure.